Previously, we observed an increased expression of LDHC in basal-like and Her2-enriched breast tumors compared to the less aggressive luminal and normal-like subtypes [19], suggesting that LDHC may play a more prominent role in basal-like or Her2-enriched tumors, which are associated with more immunogenic tumor microenvironments [21]. This evidence concerns the gene ERBB2 and neoplasm.